A KRAS pathway activation index predicting response to MEK inhibitors in patient-derived tumor xenografts.

被引：0
|
作者：
Peille, Anne-Lise [1 ]
Maier, Armin [1 ]
Foucault, Frederic [1 ]
Krumbach, Rebekka [1 ]
Kees, Tim [1 ]
Giesemann, Torsten [1 ]
Metz, Thomas [1 ]
Metcalfe, Thomas [1 ]
Fiebig, Heinz-Herbert [1 ]
Vuaroqueaux, Vincent [1 ]
机构：
[1] Oncotest GmbH, Freiburg, Germany
来源：
MOLECULAR CANCER THERAPEUTICS | 2013年 / 12卷 / 11期
关键词：
D O I：
10.1158/1535-7163.TARG-13-C30
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
C30
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Analysis of gene copy number in esophageal patient-derived tumor xenografts.
    Lukbanova, Ekaterina A.
    Timoshkina, Natalya N.
    Kolesnikov, Evgeniy N.
    Kozhushko, Mikhail A.
    Kit, Sergei
    Sanamyants, Sergey, V
    Anisimov, Aleksandr E.
    Goncharova, Anna S.
    Protasova, Tatiana P.
    Kutilin, Denis S.
    Volkova, A. V.
    Mindar, M., V
    Tkachev, Sergey Yu
    Zaikina, Ekaterina, V
    Khodakova, D., V
    Maksimov, Aleksey Yu
    Vladimirova, Liubov Yu
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] Use of RAS pathway activation or KRAS mutation status to predict cetuximab response in CRC patient-derived xenografts
    Li, Henry
    Chen, Dawei
    Guo, Sheng
    Cai, Jie
    Chen, Yiyou
    Wery, Jean-Pierre
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] MET activation and Cetuximab resistance in patient-derived tumor xenografts
    Krumbach, Rebekka
    Schuler, Julia
    Hofmann, Michael
    Fiebig, Heinz-Herbert
    Beckers, Thomas
    [J]. MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [4] Genomic characterization of a comprehensive collection of esophagogastric cancer patient-derived xenografts.
    Moy, Ryan H.
    Mattar, Marissa
    Molena, Daniela
    Strong, Vivian E.
    Jones, David Randolph
    Coit, Daniel G.
    Tang, Laura
    Maron, Steven Brad
    Hechtman, Jaclyn Frances
    de Stanchina, Elisa
    Janjigian, Yelena Y.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [5] Advances in patient-derived tumor xenografts: From target identification to predicting clinical response rates in oncology
    Rosfjord, Edward
    Lucas, Judy
    Li, Gang
    Gerber, Hans-Peter
    [J]. BIOCHEMICAL PHARMACOLOGY, 2014, 91 (02) : 135 - 143
  • [6] Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer
    Xingxiang Pu
    Ran Zhang
    Li Wang
    Yungchang Chen
    Yi Xu
    Apar Pataer
    Ismail M. Meraz
    Xiaoshan Zhang
    Shuhong Wu
    Lin Wu
    Dan Su
    Weimin Mao
    John V. Heymach
    Jack A. Roth
    Stephen G. Swisher
    Bingliang Fang
    [J]. Journal of Translational Medicine, 16
  • [7] Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer
    Pu, Xingxiang
    Zhang, Ran
    Wang, Li
    Chen, Yungchang
    Xu, Yi
    Pataer, Apar
    Meraz, Ismail M.
    Zhang, Xiaoshan
    Wu, Shuhong
    Wu, Lin
    Su, Dan
    Mao, Weimin
    Heymach, John V.
    Roth, Jack A.
    Swisher, Stephen G.
    Fang, Bingliang
    [J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2018, 16
  • [8] Maintaining Tumor Heterogeneity in Patient-Derived Tumor Xenografts
    Cassidy, John W.
    Caldas, Carlos
    Bruna, Alejandra
    [J]. CANCER RESEARCH, 2015, 75 (15) : 2963 - 2968
  • [9] Optimizing Drug Response Study Design in Patient-Derived Tumor Xenografts
    Weiss, Jessica
    Pham, Nhu-An
    Pintilie, Melania
    Li, Ming
    Liu, Geoffrey
    Shepherd, Frances A.
    Tsao, Ming-Sound
    Xu, Wei
    [J]. CANCER INFORMATICS, 2022, 21
  • [10] Patient-Derived Tumor Xenografts Why Now?
    Liu, Edison T.
    Bult, Carol J.
    Shultz, Leonard D.
    [J]. JAMA ONCOLOGY, 2016, 2 (05) : 567 - 568
12345